The FDA announces expanded access to Duke University for siblings or autologous cord blood infusions for children with cerebral palsy, hydrocephalus, hypoxic brain injury, stroke, apraxia, autism and other brain injuries.
The newest new stem cell clinical trials geared toward autism and cerebral palsy are promising, “clinical trials involving 25 children using umbilical cord, resulted in observing major improvements in communication, social behavior, and overall symptoms.”
Taking into consideration that the prevalence of Autism Spectrum Disorders (ASP) is on the rise globally and that cerebral palsy is the most common childhood motor disability, in the United States, a breakthrough stem cell in stem-cell research technology is much needed. It would revolutionize the lives of many, those living ASD and their families and loved ones.
“We are already on the cutting edge of cord blood, cord tissue and placental tissue stem cell technology, and every breakthrough means a better future for those impacted,” says Martin Smithmyer, the Founder, and CEO of Americord.
More information is available at https://www.americordblood.com/